comparemela.com
Home
Live Updates
Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate : comparemela.com
Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate
/PRNewswire/ -- Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S....
Related Keywords
Philadelphia
,
Pennsylvania
,
United States
,
Ira Pastan
,
Nicholas Nicolaides
,
Steven Kyriakos
,
Luigi Grasso
,
Raffit Hassan
,
Development Agreement
,
Us National Cancer Institute
,
Navrogen Incorporated
,
Laboratory Of Molecular Biology
,
Gi Malignancies Branch
,
Navrogen Inc
,
National Institutes Of Health
,
Cancer Research Laboratory Of Molecular Biology
,
Cooperative Research
,
Cancer Institute
,
National Institutes
,
Distinguished Investigator
,
Cancer Research
,
Molecular Biology
,
Deputy Chief
,
Chief Scientific Officer
,
Humoral Immuno Oncology
,
Chief Executive Officer
,
Navrogen
,
Ncorporated
,
comparemela.com © 2020. All Rights Reserved.